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Summary The effectiveness of cancer radiotherapy is compromised by the small proportion (approximately 5%) of patients who sustain
severe normal tissue damage after standard radiotherapy treatments. Predictive tests are required to identify these highly radiosensitive
cases. Patients with the rare, recessively inherited, cancer-prone syndrome ataxia-telangiectasia (A-T) sustain extremely severe normal
tissue necrosis after radiotherapy and their cultured cells are also highly radiosensitive. Clinically normal carriers (heterozygotes) of the A-T
gene have an increased risk of breast cancer, account for approximately 4% of all breast cancer cases and show a modest increase in cellular
radiosensitivity in vitro. It has been suggested that a substantial proportion of highly radiosensitive (HR) breast cancer patients may be A-T
heterozygotes, and that screening for mutations in the A-T gene could be used as a predictive test. We have tested this hypothesis in a group
of cancer patients who showed adverse reactions to radiotherapy. Sixteen HR breast cancer patients showing mainly acute reactions (and
seven HR patients with other cancers) were tested for ATM mutations using the restriction endonuclease fingerprinting assay. No mutations
typical of those found in obligate A-T heterozygotes were detected. If the estimate that 4% of breast cancer cases are A-T gene carriers is
correct, then ATM mutations do not confer clinical radiosernsitivity. Thege early resutlts suggest that screening for ATM mutations in cancer
patients may not be of value in predicting adverse reactions.
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There is a range in the severity of normal tissue reactions when
cancer patients receive standard radiotherapy treatment. Dose
schedules have evolved to limit the proportion ofhighly radiosensi-
tive (HR) adverse responses to about 5% of cases (Norman et al,
1988; Ribeiro et al, 1993). If it were possible to identify these HR
cases in advance oftherapy, their treatment could be adjusted and it
might then be possible to escalate the dose in the remaining patients
to improve local control and cure rates (West and Hendry, 1992).
Patients with the rare, recessively inherited, cancer-prone
syndrome ataxia-telangiectasia (A-T) who have received conven-
tional radiotherapy sustain devastating life-threatening normal tissue
necrosis (Gotoff et al, 1967; Cunliffe et al, 1975), which is more
severe than that exhibited by the 5% of 'normal' patients with HR
reactions. Cultured cells from A-Tpatients are extremely radiosensi-
tive in vitro (Taylor et al, 1975) and a modest degree of cellular
radiosensitivity has been detected in some HR patients (reviewed in
Dahlberg and Little, 1995). It has been suggested (Dahlberg and
Little, 1995; Jones et al, 1995) that a substantial proportion of HR
breast cancer patients may be A-T gene carriers (heterozygotes)
because their cells also exhibit a degree of in vitro radiosensitivity
and their frequency among breast cancer patients may be similar to
that of HR cases. This follows from the reported fourfold increased
risk ofbreast cancer among otherwise asymptomatic A-T heterozy-
gotes, such that, whereas their frequency in the general population is
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estimated to be about 0.5%, they account for approximately 4% of
all breast cancer patients (reviewed by Easton, 1994), a figure
intriguingly close to the 5% of patients with HR reactions after
radiotherapy. If these arguments are correct, testing for ATM muta-
tions among breast cancer patients could provide a predictive assay
for HR responses (Norman et al, 1992).
We have therefore screened 16 HR breast cancer patients




The breast cancer patients 1-12 (Table 1) were selected from a
large series of cases followed prospectively for their acute reac-
tions to radiotherapy (Levine et al, unpublished observations). HR
responses were defined by the development of moist desquama-
tion or premature conclusion of the treatment because of severe
reactions. The incidence of HR responses was confirmed to be
close to 5% (12 out of202, 5.9%). The breast cancer cases 13-15
were also drawn from a series ofpatients studied prospectively for
late reactions, in which the incidence ofmarked late reactions was
5% at 8 years (Ribeiro et al, 1993). The remaining patients were
considered, by their treating clinicians, to have developed an
unusually severe radiation response within the context of the
prescribed treatment schedule, and we have given details of the
treatment received and reactions experienced (Table 1 for breast
cancer patient 16 and Table 2 for non-breast cancer patients). All
patients had given informed consent.
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Table 1 Patients with carcinoma of the breast
Patient no. Prescribed treatment Reaction
1-12 40 Gy in 15 fractions over 22 days to Moist desquamation or severe erythema: the
intact breast (ten of these patients had most severely acutely reacting patients from a
premature termination of treatment because series of 202 breast cancer patients followed
of severe reactions) prospectively for acute reactions
13 40 Gy in 15 fractions over 22 days to Moist desquamation acutely. Severe density
intact breast retraction and fibrosis and severe telangiectasia
10 years from treatment
14 40 Gy in 15 fractions over 22 days to Moist desquamation acutely
intact breast (terminated at 13 fractions) (late reactions normal)
15 40 Gy in 15 fractions over 22 days to Moderate acute reaction but severe telangiectasia
intact breast 10 years from treatment
16 46 Gy in 23 fractions Severe erythema acutely. Mastectomy for breast
oedema and fibrosis 1 year after treatment
Table 2 Patients with other cancers
Patient Tumour site Prescribed treatment Reaction
17 Carcinoma of alveolus 50 Gy in 16 fractions over 22 days Severe acute reaction lasting 3
months
18 Carcinoma of cervix 45 Gy in 20 fractions over 28 days Required substitution cystoplasty for
+22.5 Gy to point A in a single severe bladder damage
insertion
19 Carcinoma of cervix 50 Gy in 25 fractions over 25 days Severe bowel and bladder damage
+ 20 Gy to point A in a single requiring defunctioning colostomy
insertion and urinary diversion
20 Carcinoma of prostate 20 Gy in five fractions over 5 days to Severe acute reaction requiring
right hemipelvis small bowel resection
21 Non-Hodgkin's lymphoma of 25 Gy in eight fractions over 9 days Moist desquamation acutely, severe
parotid induration and telangiectasia at 1 year
22 Carcinoma of larynx 52.5 Gy in 16 fractions over 22 Required laryngectomy for ulceration
days because of necrosis
23 Carcinoma of larynx 52.5 Gy in 16 fractions over 22 Required tracheostomy for radiation-induced
days oedema of larynx
cDNA preparation
Approximately 2 x 106 viable lymphocytes that had been cryo-
preserved were cultured for 3-4 days in medium containing the
mitogen phytohaemagglutinin. After harvesting the cells, approxi-
mately 2.5 gg of mRNA was extracted using a Dynabead mRNA
direct kit. One microgram of mRNA was reverse transcribed into
cDNA using the AMV reverse transcriptase system (Promega).
The reaction was diluted to a final volume of 50 pl with DEPC-
treated water. One microlitre of the preparation was added as the
template for polymerase chain reaction (PCR).
Mutation detection
The restriction endonuclease fingerprinting (REF) technique was
followed (Liu and Sommer, 1995) using 33P-labelled DNA frag-
ments. The complete coding sequence oftheATMgene was ampli-
fied in a series of eight fragments (designated 5' VI, VII and VIII,
II, I, III, V, IV 3'). Theprimer sets forthe5' fragments VI, VII, VIII
are given in Byrd et al (1996). Primers for the 3' fragments II, I, III,
V and IV were originally obtained from Y Shiloh. Conditions and
restriction enzymes were as used in Byrd et al (1996). Each digest
was run in a separate lane to aid resolution and interpretation.
RESULTS AND DISCUSSION
No ATM mutations were detected in any of the patients described
here. Using the same technique, we have identified over 50
different ATM mutations in A-T patients in the UK (Byrd et al,
1996; Lakin et al, 1996; McConville et al, 1996). A polymorphism
at 5557G-*A (aspartic acid->asparagine) was seen in 8 of the 23
patients described here, ofwhich five were heterozygous and three
homozygous for the polymorphism. Aspartic acid and asparagine
are both hydrophilic polar amino acids and, with respect to the
function ofthe ATMgene, this is not a significant change.
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Table 3 Expected frequencies of ATMmutations in HR breast cancer patients using different assumptions
Assumptions Expectations
An effect of ATMmutations on Frequency (%) of ATMmutations
Cancer risk? Clinical radiosensitivity? All patients HR patientsa
No No 0.5b 0.5
No Yesc 0.5 10.0
Yesd No 4.0 4.0
Yesd Yesc 4.0 80.0
aAssuming that 5% of all patients show HR reactions (Norman et al, 1988; Ribeiro et al, 1993). bNormal population frequency
(Easton, 1994). cAssuming that all ATMmutations lead to HR responses. dAssuming that 4% of breast cancer patients are A-T
heterozygotes (Easton, 1994).
The only other data relating to this question come from a recent
study by FitzGerald et al (1997) who screened 401 early-onset
breast cancer cases for ATM mutations (see below). Among these
were two women who had shown adverse skin reactions after
radiotherapy that were sufficiently severe to warrant interruption
oftreatment. Neither carried anATM mutation.
The frequency of ATM mutations among HR patients depends
upon three factors: (1) theproportion ofcancerpatients who are A-
Theterozygotes; (2) the likelihood thatATMmutations will lead to
HR responses afterradiotherapy; and (3) the proportion ofpatients
who exhibit HR reactions. If, for breast cancer cases, these figures
were 4% (Easton, 1994), 100% and 5% (Norman et al, 1988;
Ribeiro et al, 1993), respectively, then 80% of HR patients would
carry ATM mutations (Table 3). Thus, 13 out of 16 of our cases
would be expected to be mutation carriers. In our hands, the effi-
ciency of the REF system in detecting ATM mutations in A-T
patients is at present 70%. This figure comes from a study of 25
families in the UK in which we searched for 38 unknown muta-
tions and found 27 (Taylor et al, unpublished observations).
Taking this detection efficiency into account, we would expect to
find 9 out of 16 HR patients with mutations ifthe assumed values
for factors 1-3 (above) are correct. Our observation of zero muta-
tions in 16 cases is significantly lower than this expectation
(P < 0.001, from the confidence limits on the proportions). Thus,
either the values for factors 1 and/or 2 are overestimated and/or
the value for factor 3 is underestimated.
Recent studies that have a bearing on these estimates include
those of Vorechovsky et al (1996) who detected three ATM muta-
tions among 88 breast cancer cases (i.e. 3.4%), a figure very close
to the predicted frequency of4.0% based upon the estimates ofthe
population frequency of A-T heterozygotes and their increased
risk of breast cancer (Introduction). However, all the patients
studied by Vorechovsky et al (1996) had a family history of
tumours typical of those found in A-T families and would there-
fore be expected to be enriched forATM mutations. This suggests
that the frequency in an unselected series would have been lower
than the 3.4% observed. In the study by FitzGerald et al (1997)
referred to above, only 2 of 401 (0.5%) early-onset breast cancer
cases carried ATM mutations. On the other hand, Athma et al
(1996) have estimated that 6.6% of all breast cancers in the USA
occur in A-T heterozygotes, based upon values of 3.8 for the rela-
tive risk ofbreast cancer in A-T heterozygotes (from their studies
in 99 A-T families) and 1.4% for the population frequency ofA-T
heterozygotes in the USA (Swift et al, 1986). Although the esti-
mates of A-T heterozygote frequency among breast cancer cases
appear to be very different in the studies ofFitzGerald et al (1997)
and Athma et al (1996), it has been pointed out that there are large
uncertainties associated with these frequencies and that they are
not contradictory (Bishop and Hopper, 1997). Much larger-scale
population-based studies will be required to obtain an accurate
figure for factor 1.
The only new information relevant to factor 2 comes from
observations on three breast cancer patients identified as having
ATMmutations. Ramsay et al (1996) reported on a case with bilat-
eral disease whose fibroblasts and lymphoblastoid cells showed
elevated radiosensitivity compared with controls in clonogenic
assays. The patient received radiotherapy and developed only a
mild skin reaction and minimal late effects. The two ATM
mutation carriers identified by FitzGerald et al (1997) 'received
radiation therapy without adverse reaction'. Clearly, germline
ATMmutations do not inevitably lead to HR reactions.
We have confidence in the estimate of 5% for factor 3 because
the value comes from observations on our own patients (see
above).
The question ofwhether A-Theterozygotes are at increased risk
of cancers other than breast cancer remains controversial (Easton,
1994). If they are not, the expected frequency of ATM mutations
among non-breast cancer HR cases will be 10% ifATM mutations
always confer clinical sensitivity (Table 3). The absence of muta-
tions in seven non-breast cancer cases is compatible with this
expectation ofonly 0.7 cases.
Although the numbers of patients we have tested is only rela-
tively small, these early results do not suggest thatATM screening
ofcancerpatients before radiotherapy will be ofparticular value in
predicting HRresponses. However, we plan to extend these studies
to a larger group of HR patients, including more with late reac-
tions, as there is some evidence that the in vitro cellular radio-
sensitivity seen in HR patients correlates better with late than with
early reactions (Bumet et al, 1995; Johansen et al, 1996).
However, the clinical reaction to radiation in A-T homozygotes is
exaggerated in a continuous fashion, starting with a very severe
early reaction and progressing to tissue necrosis (Gotoff et al,
1967; Cunliffe et al, 1975). If an intermediate phenotype were to
exist in A-Theterozygotes there is no a priori reason for supposing
that it should behave in a qualitatively different manner to that in
A-T homozygotes.
Until such time as other genes that confer clinical radiosensi-
tivity have been identified and cloned, further development of
assays based upon in vitro radiation responses (West, 1995) would
appear to bejustified.
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